Skip to main content
. 2022 Jun 10;101(12):1517–1525. doi: 10.1177/00220345221100773

Figure 2.

Figure 2.

Defining the driver mutations in new ameloblastoma (AB) cell lines. Each panel pair depicts AB cell line DNA-seq reads indicative of driver mutation (left: Integrative Genomics Viewer screenshot), along with Sanger sequencing validation of mutation in the parent tumor (right: sequence chromatogram). (A) NRAS-Q61R mutation in AB1T cells. (B) NRAS-Q61K mutation in AB6T cells. (C) SMO-L412F mutation in AB2T cells. (D) KRAS-G12R mutation in AB2T cells. (E) SMO-L412F mutation in AB3T cells. (F) FGFR2-C383R mutation in AB3T cells. (G) PIK3CA-N345K mutation in AB3T cells. (H) BRAF-V600E mutation in AB4T cells.